Engineered mesoporous silica reduces long-term blood glucose, HbA1c, and improves metabolic parameters in prediabetics
Jeanha Baek, Ghislaine Robert-Nicoud, Carmen Herrera Hidalgo, Melissa L Borg, Muhammad N Iqbal, Roger Berlin, Maria Lindgren, Erik Waara, Anna Uddén, Kirsi Pietiläinen, Tore Bengtsson, Jeanha Baek, Ghislaine Robert-Nicoud, Carmen Herrera Hidalgo, Melissa L Borg, Muhammad N Iqbal, Roger Berlin, Maria Lindgren, Erik Waara, Anna Uddén, Kirsi Pietiläinen, Tore Bengtsson
Abstract
Aim: To investigate the effect of oral consumption of engineered mesoporous silica particles, SiPore15®, on long-term blood glucose levels and other metabolic parameters in individuals with prediabetes and newly diagnosed Type 2 diabetes. Method: An open-label, single-arm, multicenter trial was conducted in which SiPore15 was consumed three times daily for 12 weeks. Hemoglobin A1c (HbA1c, primary end point) and an array of metabolic parameters were measured at baseline and throughout the trial. Result: SiPore15 treatment significantly reduced HbA1c by a clinically meaningful degree and improved several disease-associated parameters with minimal side effects. Conclusion: The results from this study demonstrate the potential use of SiPore15 as a treatment for prediabetes that may also delay or prevent the onset of Type 2 diabetes.
Trial registration: ClinicalTrials.gov NCT03823027.
Keywords: HbA1c; Type 2 diabetes; diabetes prevention; medical device; mesoporous silica particles; prediabetes.
Source: PubMed